Phoenix Biosystem is developing enabling technologies for continuous monitoring of analytes. While a great many innovative technologies have been proposed, only a fraction are in advanced stages of development. ? ? Blood gas, electrolyte and glucose values are a necessary diagnostic measurement in the management of critically ill, ventilated patients in the intensive care unit (ICU). The frequency of blood sampling is usually determined by the severity of the condition and clinical practice. A drawback to scheduled blood sampling is that changing conditions may be missed. In critical situations the practitioner may have to wait for a blood sample to be drawn and taken to the laboratory, which may or may not be in close proximity to the ICU. With the advent of continuous monitoring, treatment modalities can be proactive rather than reactive. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44AA014115-04
Application #
7234717
Study Section
Special Emphasis Panel (ZAA1-CC (31))
Program Officer
Gentry, Thomas
Project Start
2002-09-30
Project End
2009-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
4
Fiscal Year
2007
Total Cost
$407,193
Indirect Cost
Name
Phoenix Biosystem, Inc.
Department
Type
DUNS #
032758695
City
Pleasanton
State
CA
Country
United States
Zip Code
94566